New Gene Methylation Test for Prostate Cancer Available
Posted on: Friday, 16 May 2008, 09:00 CDT
RARITAN, N.J., May 16 /PRNewswire/ -- Veridex, LLC announced today that its licensing collaborator, Laboratory Corporation of America Holdings (LabCorp), has commercially launched a new gene methylation test for prostate cancer. The new assay uses the biological specificity of 'DNA methylation' in prostate cancer, detecting the methylation of the gene GST-Pi. Methylation is a modification of DNA that occurs primarily in cancer. Veridex is developing the methylation markers in this tissue assay, GST-Pi, along with other markers, for a urine-based screening test for prostate cancer.
Prostate cancer is the leading cause of cancer death in men in the U.S., with more than 230,000 cases diagnosed annually.
LabCorp licensed the methylation technology from Veridex in 2007. Veridex licensed this technology from OncoMethylome Sciences, S.A. (OMS).
About Veridex
Veridex, LLC, a Johnson & Johnson company, develops cancer diagnostic products that will enable earlier disease detection as well as more accurate staging, monitoring and therapeutic selection. The company is initially developing two complementary product lines: CellSearch(TM) assays that identify, enumerate and characterize circulating tumor cells directly from whole blood; and GeneSearch(TM) assays that use molecular technology to diagnose, stage and more accurately characterize tumors. For additional information, please visit http://www.veridex.com/
Veridex, LLC
CONTACT: Jessica Giangaspero, +1-908-218-8124
Web site: http://www.veridex.com/
Source: PRNewswire
Related Articles
- Call Issued To Reconsider Breast Cancer And Prostate Cancer Screening
- FDA Expands Clearance to Veridex Cancer Diagnostic System
- Aphios Corporation Announces Licensing of Non-Toxic Vitamin D Analog for Prostate Cancer From Boston University Medical School
- Smaller Prostate Size, More Aggressive Cancer
- No Link Between Diabetes, Aggressive Prostate Cancer
- Progenics and Cytogen Report Potent Anti-Tumor Activity for Experimental Prostate Cancer Drug
- Cancer of Prostate a Top Killer in Utah
- PSA Testing for Prostate Cancer Is Tricky
- Specialists Fight Cancer of Prostate -- Killer Gets New Attention As Doctors Try to Determine Causes, Prevention
- Richland Firm Introduces Promising Isotope for Cancer Treatment; Prostate Cancer Patient Receives New Seed Therapy By IsoRay Medical, Inc. In a Worldwide First for Cesium-131
 |
 |
User Comments (0)
RSS Feeds